Condition: Vaccine Immunity in CAR-T Cell Therapy Recipients · Sponsor: Insel Gruppe AG, University Hospital Bern
The goal of this observational study is to learn about vaccine immunity in patients with B-cell malignancies treated by chimeric antigen receptor T-cell therapies (CAR-T). The main questions it aims to answer are: * Do CAR-T cell therapy recipients lose vaccine protection against common vaccine-preventable pathogens * Are current re-vaccination recommendations sufficient in restoring vaccine-protection * Is this restored vaccine-protection after CAR-T cell therapy lost faster than usual * Do clinical or immunological factors predict vaccine response after CAR-T cell therapy
This description comes directly from the study's public registry record.
Lukas N Baumann, MD · +41 31 664 3069 · lukas.baumann2@insel.ch
Cédric Hirzel, PD, MD · +41 31 66 4 01 17 · cedric.hirzel@insel.ch
Always discuss trial participation with your own doctor first.
| University Hospital Bern | Bern, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06333275